To test the potential application of KYA1797K in humans, we established tumor organoids derived from CRC patient tissues harboring both APC (truncated form, Arg216*stop) and KRAS (Gly12Ser) mutations, which were identified by whole exome sequencing (Fig. 6a). This evidence concerns the gene KRAS and neoplasm.